Your browser doesn't support javascript.
loading
Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
Ruggeri, M; Rolli, F R; Kondili, L A; Drago, C; De Solda, F; Nappi, C; Cicchetti, A.
Afiliação
  • Ruggeri M; a Institute of Economic Policy and School of Health Economics and Management , Università Cattolica del Sacro Cuore , Rome , Italy.
  • Rolli FR; b School of Health Economics and Management , Università Cattolica del Sacro Cuore , Rome , Italy.
  • Kondili LA; c Center for Global Health , Istituto Superiore di Sanità , Rome , Italy.
  • Drago C; d Università Niccolò Cusano , Rome , Italy.
  • De Solda F; e Center for Global Health , Bristol-Myers Squibb , Rome , Italy.
  • Nappi C; e Center for Global Health , Bristol-Myers Squibb , Rome , Italy.
  • Cicchetti A; b School of Health Economics and Management , Università Cattolica del Sacro Cuore , Rome , Italy.
Expert Rev Pharmacoecon Outcomes Res ; 19(3): 363-374, 2019 Jun.
Article em En | MEDLINE | ID: mdl-30351994
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite C Crônica / Sofosbuvir / Imidazóis Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite C Crônica / Sofosbuvir / Imidazóis Idioma: En Ano de publicação: 2019 Tipo de documento: Article